🎯
LATEST VERIFIED AI EXECUTION
Our quantitative model captured a massive +11.41% net profit on $TIP.MI in just 121h 17m. Stop guessing, start executing.
$KLRS
Kalaris Therapeutics Inc
UNITED STATESFREE PREVIEW
AVG HISTORICAL GAP-0.60%
MAX GAP RECORD-2.71%
PREMIUM
AI ACCURACY RATE92.4%
Unlock AI Insights 🔓LAST 10 EARNINGS GAPS (%)
QUANTITATIVE LIVE RADAR BLOTTER
Institutional execution stream for $KLRS
EXECUTIONS0
WIN RATE••.•%
NET ROI+•••.••%
| Execution Date | Strategy & Setup | Direction | Execution Range | Hold Time | Exit Trigger | Net PnL |
|---|---|---|---|---|---|---|
| RADAR SCANNING: WAITING FOR NEXT CATALYST | ||||||
🔒 Institutional Data Protected
UNLOCK FULL BLOTTERExact execution prices, stop-loss triggers, and full trade logs are reserved for PRO members.
VOLATILITY & BIAS PROFILE
AVG VOLATILITY2.3%
Bullish Gaps
Bearish Gaps
Neutral
Intelligence Brief
Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases. The company was founded by Srinivas Akkaraju, Mike Dybbs and Napoleone Ferrara in 2019 and is headquartered in Berkeley Heights, NJ. Read full dossier
CURRENT AI SIGNAL
BULLISH STRONG
🔓 REVEAL SIGNAL